<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05008549</url>
  </required_header>
  <id_info>
    <org_study_id>AFCRO-140</org_study_id>
    <nct_id>NCT05008549</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Synergistic Effects of a Cranberry Beverage on Cognitive Function</brief_title>
  <official_title>A Randomized, Double-blinded, Placebo-controlled, Crossover Study, to Assess the Synergistic Effects of a Cranberry Beverage on Cognitive Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ocean Spray Cranberries, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Atlantia Food Clinical Trials</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ocean Spray Cranberries, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to determine the effect short-term dosing (7 days) of a placebo beverage,&#xD;
      cranberry juice, cranberry juice + lemon balm extract, cranberry juice + tart cherry powder,&#xD;
      or cranberry juice + L-theanine or L-theanine beverage on cognitive function and mood in&#xD;
      healthy adults (18-45 years). The study will include measures of attention, alertness,&#xD;
      performance, and mood/stress.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 26, 2021</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>A randomized, double-blinded, placebo-controlled, crossover study, to assess the synergistic effects of a cranberry beverage on cognitive function in healthy adults aged 18-45.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate in healthy adults the effect of 7-day consumption of cranberry beverages compared to placebo on attention.</measure>
    <time_frame>7 days</time_frame>
    <description>Change in Accuracy of Attention and Change in Speed of Attention composite scores outcomes from Baseline to each treatment phase (V3-8), assessed using the COMPASS cognitive assessment tool.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate in healthy adults the effect of 7-day consumption of cranberry beverages compared to placebo on measures of focus.</measure>
    <time_frame>7 days</time_frame>
    <description>Change in Overall % accuracy scores outcomes from Baseline to each treatment phase (V3-8), assessed using the STROOP task in the COMPASS cognitive assessment tool.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate in healthy adults the effect of 7-day consumption of cranberry beverages compared to placebo on measures of alertness.</measure>
    <time_frame>7 days</time_frame>
    <description>Change in Alertness scores outcomes from Baseline to each treatment phase (V3-8), assessed using the self-rated Alertness Visual Analogue Scale in the COMPASS cognitive assessment tool.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate in healthy adults the effect of 7-day consumption of cranberry beverages compared to placebo on measures of cognition (accuracy of performance).</measure>
    <time_frame>7 days</time_frame>
    <description>Change in Accuracy of Performance composite scores outcomes from Baseline to each treatment phase (V3-8), assessed using the COMPASS cognitive assessment tool.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate in healthy adults the effect of 7-day consumption of cranberry beverages compared to placebo on measures of cognition (speed of performance).</measure>
    <time_frame>7 days</time_frame>
    <description>Change in Speed of Performance composite scores outcomes from Baseline to each treatment phase (V3-8), assessed using the COMPASS cognitive assessment tool.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate in healthy adults the effect of 7-day consumption of cranberry beverages compared to placebo on mood.</measure>
    <time_frame>7 days</time_frame>
    <description>Change in Total Mood Disturbance scores from Baseline to each subsequent visit (V3-8), assessed using the Profile of Mood States-Short Questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate in healthy adults the effect of 7-day consumption of cranberry beverages compared to placebo on stress.</measure>
    <time_frame>7 days</time_frame>
    <description>Change in salivary cortisol from Baseline to each treatment phase (V3-8).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>To evaluate in healthy adults the safety and tolerability of 7-day consumption of cranberry beverages compared to placebo (Proportion of Adverse Events).</measure>
    <time_frame>7 days</time_frame>
    <description>Proportion of Adverse Events per treatment phase by product causality.</description>
  </other_outcome>
  <other_outcome>
    <measure>To evaluate in healthy adults the safety and tolerability of 7-day consumption of cranberry beverages compared to placebo (Incidence of Adverse Events).</measure>
    <time_frame>7 days</time_frame>
    <description>Incidence of mild, moderate, and severe Adverse Events per treatment phase by product causality.</description>
  </other_outcome>
  <other_outcome>
    <measure>To evaluate in healthy adults the safety and tolerability of 7-day consumption of cranberry beverages compared to placebo (Incidence of Serious Adverse Events).</measure>
    <time_frame>7 days</time_frame>
    <description>Incidence of Serious Adverse Events per treatment phase by product causality.</description>
  </other_outcome>
  <other_outcome>
    <measure>To evaluate in healthy adults the safety and tolerability of 7-day consumption of cranberry beverages compared to placebo (Blood Pressure).</measure>
    <time_frame>7 days</time_frame>
    <description>Change in Blood Pressure from Baseline to each subsequent visit (V3-8).</description>
  </other_outcome>
  <other_outcome>
    <measure>To evaluate in healthy adults the safety and tolerability of 7-day consumption of cranberry beverages compared to placebo (Heart Rate).</measure>
    <time_frame>7 days</time_frame>
    <description>Change in Heart Rate from Baseline to each subsequent visit (V3-8).</description>
  </other_outcome>
  <other_outcome>
    <measure>To evaluate in healthy adults the safety and tolerability of 7-day consumption of cranberry beverages compared to placebo (Body Temperature).</measure>
    <time_frame>7 days</time_frame>
    <description>Change in Body Temperature from Baseline to each subsequent visit (V3-8).</description>
  </other_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Attention</condition>
  <condition>Mood</condition>
  <arm_group>
    <arm_group_label>First Product Order: order not stated to protect study blinding</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive each of the 6 study products sequentially in a cross-over design, consuming one study product for 7 days, followed by a 7 day wash-out period before beginning the next product in the sequence.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Second Product Order: order not stated to protect study blinding</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive each of the 6 study products sequentially in a cross-over design, consuming one study product for 7 days, followed by a 7 day wash-out period before beginning the next product in the sequence</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Third Product Order: order not stated to protect study blinding</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive each of the 6 study products sequentially in a cross-over design, consuming one study product for 7 days, followed by a 7 day wash-out period before beginning the next product in the sequence</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fourth Product Order: order not stated to protect study blinding</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive each of the 6 study products sequentially in a cross-over design, consuming one study product for 7 days, followed by a 7 day wash-out period before beginning the next product in the sequence</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fifth Product Order: order not stated to protect study blinding</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive each of the 6 study products sequentially in a cross-over design, consuming one study product for 7 days, followed by a 7 day wash-out period before beginning the next product in the sequence</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sixth Product Order: order not stated to protect study blinding</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive each of the 6 study products sequentially in a cross-over design, consuming one study product for 7 days, followed by a 7 day wash-out period before beginning the next product in the sequence</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Cranberry Juice Product</intervention_name>
    <description>The cranberry juice product contains 100 % cranberry juice (ingredients: water, cranberry juice concentrate)&#xD;
The cranberry juice + lemon balm extract product contains 100 % cranberry juice (ingredients: water, cranberry juice concentrate) + lemon balm extract (300 mg, Robertet Groupe)&#xD;
The cranberry juice + tart cherry juice product contains 100 % cranberry juice (ingredients: water, cranberry juice concentrate) + 3 g tart cherry powder (Cherry PURE)&#xD;
The cranberry juice + L-theanine product contains 100% cranberry juice (ingredients: water, cranberry juice concentrate) + 200 mg L-theanine (Suntheanine, Taiyo International)&#xD;
L-theanine + placebo product contains L-theanine (200 mg, Suntheanine, Taiyo International) + placebo (see 5.2.1)&#xD;
The placebo product contains water, dextrose, citric acid, malic acid, fumaric acid, natural flavor, Red #40, xanthan gum, Blue #1, gum Arabic, Reb M, Steviol glycosides, and ester gum.</description>
    <arm_group_label>Fifth Product Order: order not stated to protect study blinding</arm_group_label>
    <arm_group_label>First Product Order: order not stated to protect study blinding</arm_group_label>
    <arm_group_label>Fourth Product Order: order not stated to protect study blinding</arm_group_label>
    <arm_group_label>Second Product Order: order not stated to protect study blinding</arm_group_label>
    <arm_group_label>Sixth Product Order: order not stated to protect study blinding</arm_group_label>
    <arm_group_label>Third Product Order: order not stated to protect study blinding</arm_group_label>
    <other_name>Cranberry Juice + Lemon Balm Extract Product</other_name>
    <other_name>Cranberry Juice + Tart Cherry Juice Product</other_name>
    <other_name>Cranberry Juice + L-theanine Product</other_name>
    <other_name>L-theanine + Placebo Product</other_name>
    <other_name>Placebo Product</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        To be eligible for inclusion, the participant must fulfil all of the following criteria:&#xD;
&#xD;
          1. Be able to give written informed consent and willing/able to comply with study&#xD;
             procedures.&#xD;
&#xD;
          2. Be between 18 and 45 years, inclusive.&#xD;
&#xD;
          3. Is in general good health, as determined by the investigator.&#xD;
&#xD;
          4. Has a BMI between ≥20 - ≤35 kg/m2.&#xD;
&#xD;
          5. Has had a stable body weight (≤5 % change) over the past 3-months.&#xD;
&#xD;
          6. Has a Beck Depression Inventory II score ≤20 at screening.&#xD;
&#xD;
          7. Willing to discontinue consumption of wine and dark red/blue colored fruits and&#xD;
             polyphenol-rich fruits (e.g., pomegranate, blueberries, grapes), lemon balm, tart&#xD;
             cherry powder, and L-Theanine for the two weeks leading up to the study (from the&#xD;
             Screening visit V1 to baseline V2) and during the study.&#xD;
&#xD;
          8. Willing and able to avoid consumption of any cranberry juice, whole cranberries, and&#xD;
             dried cranberries for the two weeks leading up to the study (from the Screening visit&#xD;
             V1 to baseline V2) and during the study, excluding the study beverage.&#xD;
&#xD;
          9. Is willing to provide saliva samples.&#xD;
&#xD;
         10. Maintain current level of physical activity and dietary habits throughout the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Participants that meet any of the following criteria will be excluded from the trial:&#xD;
&#xD;
          1. Has a known or suspected allergy to components of the investigational product (e.g.,&#xD;
             cranberries, tart cherry, lemon balm, L-theanine).&#xD;
&#xD;
          2. Uncontrolled blood pressure or untreated hypertension.&#xD;
&#xD;
          3. Consumes &gt;2 alcoholic beverages per day or &gt;14 per week.&#xD;
&#xD;
          4. Major chronic illness or health condition that might interfere with the study outcomes&#xD;
             at the discretion of the study clinician or principal investigator.&#xD;
&#xD;
          5. Use of antidepressant, anxiolytic, Central Nervous System stimulant, antipsychotic,&#xD;
             antimanic, anti-inflammatory (except for aspirin and non-steroidal anti-inflammatory&#xD;
             drugs [NSAIDS]. Multivitamins, vaccines, gender affirming hormones, HIV prevention&#xD;
             medications, allergy medications, topical steroids are allowed for inclusion.)&#xD;
&#xD;
          6. Individuals who smoke or use nicotine patches or gum or e-cigarettes, or marijuana&#xD;
             (within the past 6 months).&#xD;
&#xD;
          7. Individuals who have experienced a stroke or a head injury with concussion, loss of&#xD;
             consciousness or seizures.&#xD;
&#xD;
          8. History or clinical manifestation of any significant neurologic disorder in the&#xD;
             opinion of the investigator and/or study clinician.&#xD;
&#xD;
          9. Any disease, that by the investigator's judgement, could interfere with the intestinal&#xD;
             barrier function, including Celiac disease (Lactose intolerance or acid reflux are&#xD;
             allowed for inclusion).&#xD;
&#xD;
         10. Participants may not be receiving treatment involving experimental drugs. If the&#xD;
             participant has been in a recent experimental trial, these must have been completed&#xD;
             not less than one month prior to this trial.&#xD;
&#xD;
         11. Desire and/or plans on changing current diet and/or exercise regime during the&#xD;
             participation of this trial.&#xD;
&#xD;
         12. Individuals who are pregnant or lactating.&#xD;
&#xD;
         13. Individuals currently of childbearing potential, but not using an effective method of&#xD;
             contraception, as determined by the investigator.&#xD;
&#xD;
         14. History of heavy caffeinated beverage consumption (&gt;400 mg caffeine/day - or 4 cups of&#xD;
             coffee per day) within past 2 weeks prior to the Screening Visit (V1), or before their&#xD;
             Baseline Visit (V2).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alice Eggleston, PA-C, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Atlantia Clinical Trials Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elizabeth Johnson, PhD</last_name>
    <phone>508-923-3232</phone>
    <email>eljohnson@oceanspray.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Atlantia Clinical Trials Ltd</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alice Eggleston, PA-C, MPH</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 14, 2021</study_first_submitted>
  <study_first_submitted_qc>August 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2021</study_first_posted>
  <last_update_submitted>August 9, 2021</last_update_submitted>
  <last_update_submitted_qc>August 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

